PAVmed Inc. (PAVM): Nasdaq/NYSE listing notice — PAVmed receives Nasdaq delisting notice for MVLS below $35M minimum

PAVmed Inc.

Nasdaq notified PAVmed on March 7, 2024 that MVLS was below $35M for 30 consecutive days through March 6.
Company has 180 calendar days (until Sept 3, 2024) to regain compliance; MVLS must close at $35M+ for 10 consecutive days.
If compliance not regained by deadline, Nasdaq will issue written notification that securities are subject to delisting.
The notice does not immediately affect trading; PAVM and PAVMZ continue uninterrupted on Nasdaq Capital Market.
PAVmed intends to evaluate all available options to regain compliance with Nasdaq listing standards.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

PAVmed Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5550(b)(2)

Exact text from the filing

March 7, 2024, PAVmed Inc. (the “ Company ”) received a notice from the Listing Qualifications Department of The Nasdaq Stock Market (“ Nasdaq ”) stating that, for the last 30 consecutive business days (through March 6, 2024), the market value of the Company’s listed securities (“ MVLS ”) had been below the minimum of $35 million required for continued inclusion on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2). The notification letter stated that the Company would be afforded 180 calendar days (until September 3, 2024) to regain compliance. In order to regain compliance, the C

View on SEC.gov

Browse all listing & compliance notices →

PAVmed Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-009411

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.